Session 7 – Cell & Gene Therapies Date: 26 July (Friday) 9:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
GM Cell & Gene Therapy Strategy and Business Development
Phil is a passionate advocate for regenerative medicine and the role it will play in treating diseases as global healthcare systems transition to precision health models.
An entrepreneurial and strategic international business leader, Phil has led marketing, business development, and innovation in start-up and established biotechnology companies. Additionally, he was an instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center. His business and academic experiences give him a unique perspective of the global opportunities and challenges of the biotechnology industry.
Since joining GE Healthcare in May 2013, Phil has played a key role in growing and aligning core business functions to meet the industry’s biomanufacturing needs. He was integral in developing the business strategy for the successful Biosafe and Asymptote acquisitions, important deals for the business’ strategic growth.
A recognized authority in regenerative medicine, Phil is a sought-after speaker at industry events. In addition to his professional responsibilities, he sits on the board of several organizations, including the Centre for Commercialization of Regenerative Medicine (CCRM), Toronto, Ontario and the Alliance for Regenerative Medicine, Washington, DC.
Phil held leadership positions at Life Technologies, Atto Bioscience, BD Biosciences, and Lonza Bioscience before joining GE Healthcare. Session Speech Title & Synopsis: Industrializing Cell & Gene Therapies: Designing and Managing a Complex Therapeutic Supply Chain
This presentation will compare and contrast key elements of biologics and cell & gene therapy manufacturing and delivery from the perspective of anticipated future market demand. The challenges of commercializing living therapies include scale up and scale out manufacturing, cold-chain logistics, data management, facilities design and utilization, as well as a host of other critical supply chain elements. We’ll look at how process developers introduce advanced manufacturing capabilities to realize the commercial and clinical potential of this novel class of medicines